ERBB2 and breast carcinoma: Despite the notion of dual-targeting opportunity in patients with HER-2 and hormone-positive breast cancer, the development of endocrine and anti-HER2 combinations was relatively slow, [19] possibly due to resistance to conventional endocrine treatments in the HER-2 positive breast cancer [20].